Claire Scudder

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Timothy Iveson, Rachel Kerr, Mark Saunders et al. · The Lancet Oncology · 2018 · 188 citations · Full text

Medicine, Oncology, Pharmacology +16

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Rachel Kerr, Sharon Love, Eva Segelov et al. · The Lancet Oncology · 2016 · 149 citations

Medicine, Oncology, Pharmacology +11

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at <i>DPYD</i> and a putative role for <i>ENOSF1</i> rather than <i>TYMS</i>

Dan Rosmarin, Claire Palles, Alistair T. Pagnamenta et al. · Gut · 2014 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial

M. Loredana Marcovecchio, Linda S. Wicker, David B. Dunger et al. · Wellcome Open Research · 2020 · 28 citations · Full text

Life Sciences, Endocrinology, Immunology +17

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

Vincas Urbonas, Dirk Schadendorf, Lisa Zimmer et al. · Annals of Oncology · 2018 · 23 citations · Full text

Medicine, Oncology, Pharmacology +17